Who has been buying Jeil Bio stock?

2 distinct insiders have filed 6 disclosed insider purchases in Jeil Bio (052670), most recently on 2026-02-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Jeil Bio have?

Jeil Bio has 6 buy-side and 0 sell-side disclosures on record, covering ₩123M ($86K) in total reported value, spanning 2024-12-02 to 2026-02-24.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Jeil Bio 052670

Company

제일바이오Jeil Bio

Insiders

Buys

Total Value

₩123M ($86K)

Avg Return

-12.66%

Last Filing

2026-02-24

Jeil Bio (052670) has 6 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩123M ($86K) in reported transaction value. The earliest filing StockDrifts holds for Jeil Bio is dated 2024-12-02; the most recent is 2026-02-24. Across these filings the average return since disclosure is -12.66%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-02-24	BUY	Market Buy	심의정 Sim Ui-jeong	Sales Manager	735	-	-	-
2026-02-24	BUY	Market Buy	심광경 Shim Kwang-kyung	Honorary Chairman	590	-	-	-
2026-02-23	BUY	Market Buy	심의정 Sim Ui-jeong	Sales Manager	245	-	-	-
2026-02-23	BUY	Market Buy	심광경 Shim Kwang-kyung	Honorary Chairman	277	-	-	-
2026-02-20	BUY	Market Buy	심광경 Shim Kwang-kyung	Honorary Chairman	278	₩320,000	+0.0%	₩89M ($62K)
2026-02-19	BUY	Market Buy	심광경 Shim Kwang-kyung	Honorary Chairman	80	₩428,500	-25.3%	₩34M ($24K)
2026-02-09	SELL	주식병합	심광경 Shim Kwang-kyung	Honorary Chairman	-2.1M	₩625,000	+48.8%	₩1.3T ($927.9M)
2026-02-09	SELL	주식병합	심의정 Sim Ui-jeong	Sales Manager	-4.2M	₩625,000	+48.8%	₩2.6T ($1.8B)
2026-02-09	SELL	주식병합	강동일 Kang Dong-il	CEO	-249.9K	₩625,000	+48.8%	₩156.2B ($108.5M)
2025-06-23	BUY	자사주상여금	강동일 Kang Dong-il	CEO	250.1K	₩2,080	+15284.6%	₩520M ($361K)
2025-06-23	BUY	자사주상여금	심의정 Sim Ui-jeong	Sales Manager	67.5K	₩2,080	+15284.6%	₩140M ($97K)
2025-06-23	BUY	자사주상여금	심광경 Shim Kwang-kyung	Honorary Chairman	67.5K	₩2,080	+15284.6%	₩140M ($97K)
2024-12-02	BUY	합병	심의정 Sim Ui-jeong	Sales Manager	67.9K	₩2,080	+15284.6%	₩141M ($98K)

Frequently asked questions

Who has been buying Jeil Bio stock?: 2 distinct insiders have filed 6 disclosed insider purchases in Jeil Bio (052670), most recently on 2026-02-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Jeil Bio have?: Jeil Bio has 6 buy-side and 0 sell-side disclosures on record, covering ₩123M ($86K) in total reported value, spanning 2024-12-02 to 2026-02-24.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.